There is on-going development of generic EU CTD Dossier of Repaglinide, tablets, 0.5/1/2 mg.
Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.
Repaglinide belongs to the meglitinide class of blood glucose-lowering drugs.
Repaglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the beta cells. This depolarizes the beta cells, opening the cells' calcium channels, and the resulting calcium influx induces insulin secretion.
More details at: http://www.rxlist.com/prandin-drug.htm.Read also at Pharmaceutical Licensing Network
Newer news items
|< Prev||Next >|
Networking Tips & Tricks for Career Development
Networking in professional, social, and other settings has become an increasingly important aspect of a career development as people now tend to move from one company to another more frequently.
We have noticed that several top level recruiters are using Farmavita.Net. Your profesional connections will tell them much more than your CV.